A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Balixafortide (Primary) ; Eribulin
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Polyphor
- 02 Jun 2017 Results (n=24) from the dose expansion cohort of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 31 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 31 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History